SARS-CoV-2 IgG (RBD & NP) ARRAY
–
Uniquely measuring antibodies reactive to both RBD and NP
Uniquely measuring antibodies reactive to both RBD and NP
- Simultaneous detection of IgG antibodies to RBD & NP maximises assay sensitivity reducing false negatives
- Confirmation of an adaptative immune response to SARS-CoV-2
- Distinguish vaccinated from naturally infected individuals
- Specificity of 99.5% and sensitivity of 100% ≥ 14 days post SARS-CoV-2 PCR confirmation
- Identify incidence of SARS-CoV-2 infection in vaccinated individuals
- Qualitative and semi-quantitative results provided
The Randox SARS-CoV-2 IgG (RBD & NP) array utilises patented biochip technology to simultaneously detect IgG antibodies against both leading COVID-19 diagnostic antigens; Spike Receptor Binding Domain (RBD) and Nucleocapsid protein (NP).
Maximum sensitivity is ensured through detection of antibodies against both proteins making the assay superior compared to other commercially available serology tests where false negative results are common. Measurement of both RBD and NP IgG antibodies also provides an opportunity to discriminate vaccinated versus naturally infected individuals based on leading vaccine candidates.
Serology testing plays a pivotal role in both research and surveillance of SARS-CoV-2, helping to overcome some of the many challenges presented by the pandemic. As well as validating the effectiveness of vaccine trials, antibody tests may be used to effectively determine the percentage of a population that have already been infected and to measure antibody levels in plasmapheresis donations. It may also be used to complement PCR testing, antibody detection in combination with RT-PCR increases the detection window and minimises false negative PCR results.
The new array has a specificity of 99.5% and sensitivity of 100% more than 14 days post PCR test with a sensitivity of 92.3% 0-14 days post PCR confirmation. The Randox SARS-CoV-2 antibody array will also include a calibrator and controls are available to order.
SARS-CoV-2 IgG (RBD & NP) Array
The S protein consisting of S1 and S2 subunits is located on the surface of the SARS-CoV-2 virus making it highly immunogenic. The S protein plays an important role in viral attachment, fusion and entry to the host cell, as such it serves as a target for the development of antibodies, entry inhibitors and vaccines. The Receptor Binding Domain (RBD) located on the S1 subunit is the key target for neutralising antibodies. Unlike N protein, RBD is associated with less cross reactivity with other coronaviruses and is therefore highly specific to SARS-CoV-2.
The nucleocapsid protein (NP) is abundantly expressed in individuals infected with SARS-CoV-2 and is highly immunogenic. N protein is normally very conserved, because of this homology recent research cautions against the use of serology tests that detect antibodies against the N protein alone.
Available Platforms
Evidence Investigator
Cost effective and efficient semi-automated multiplex testing solution
Medium to high throughput (54 samples in 1.5 hours)
Limited sample volume requirement (10ul)
Comprehensive immunoassay and molecular test menu available
Evidence+
Fully automated batch immunoanalyser for
faster testing & accurate results
High throughput (2070 samples per day)
Limited sample volume requirement (10ul)
Comprehensive immunoassay test menu available
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
